Tag Archive for: Cancer

Theragnostics Announces that its Radiotherapeutic for Treatment of Glioblastoma Multiforme has been Awarded UK’s MHRA Innovation Passport

/in

Promising non-clinical results support Phase 1 clinical study in recurrent GBM Commitment to ensuring I-123 PARPi is available to treat the unmet medical need of patients diagnosed with primary and recurrent GBM LONDON, UK, 10 February 2022 – Theragnostics, which is developing radiopharmaceuticals for imaging and treatment of cancer, today announces that its novel I-123 […]

Read more

CellCentric secures investment from the American Cancer Society’s impact venture capital fund

/in

Inobrodib is the first drug to target p300/CBP, a new way to treat specific cancers.  Following a successful Phase I campaign, new funding will be used to progress clinical development towards to pivotal registration trials. Cambridge, UK, 26 January 2022 – CellCentric, a clinical stage, private biotechnology company pioneering small molecule inhibition of p300/CBP to treat […]

Read more

ISA to present key learnings for cancer vaccine development at the ESMO Immuno-Oncology Congress

/in

Oegstgeest, December 7, 2021 – ISA’s very own Chief Scientific Officer, Cornelis “Kees” Melief, M.D., Ph.D., will be presenting key learnings in cancer vaccine development in an educational session at the ESMO Immune-Oncology Congress 2021, taking place on 8th – 11th December 2021 in Geneva, Switzerland and online. Read more…

Read more

ATP Launches Adendra Therapeutics, a New Kind of Immunotherapy Company Deploying Novel Insights into Dendritic Cell Biology, with $53M Series A

/in

Co-founded with renowned immunologist Professor Caetano Reis e Sousa of the Francis Crick Institute First UK-based ATP portfolio company NEW YORK and LONDON, December 7, 2021—ATP (Apple Tree Partners), a leader in life sciences venture capital, today announced the launch of Adendra Therapeutics Ltd. (“Adendra”), a company that will discover and develop treatments for cancers and autoimmune diseases […]

Read more

Joint Development Agreement with 4basebio PLC for novel CAR T-cell production methods

/in

Leucid Bio: Joint Development Agreement with 4basebio PLC for novel CAR T-cell production methods 4basebio PLC (AIM: 4BB), the specialist life sciences group focused on exploiting intellectual property in the field of cell and gene therapies and DNA vaccines, is pleased to announce a Joint Development Agreement (“JDA”) between its wholly owned subsidiary 4basebio Discovery […]

Read more
© Optimum Strategic Communications.